A new drug application has been filed with the FDA claiming to treat chronic fatigue syndrome (ME/CFS) and long COVID. Since “investigational new drugs” (INDs) documents treating ME/CFS are not very commonly presented to the FDA, this indicated the company is confident in its treatment to begin clinical traits for FDA drug approval.
At first glance, the drug – Inspiritol – doesn’t seem a good fit for treating ME/CFS or long COVID as it was first developed to treat COPD. Inspiritol is a nebulizer, inhaled medication, that has anti-oxidant, anti-inflammatory, and broad-spectrum anti-viral and anti-bacterial properties.
The formulation was co-developed by John Salerno, MD, and an environmental engineer named George E. Hoag, PhD. The two tested the effects of the new drug with Dr. Liisa Selin and Dr. Anna Gil at the UMass Chan Medical School. The team was amazed at how well the new drug fit the mysterious disease. After running tests on a few patients with long COVID and ME/CFS who had been on Inspiritol for 2-5 months, they found “dramatic improvement of these patients symptoms.”
The evidence so far is encouraging enough for Inspiritol, Inc to begin clinical trials and the team is currently preparing for nonclinical and clinical testing.
